Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Thyra Maltese

Physician Assistant Summerville, SC Physician Assistant

NPI 1861938490 CMS profile 10950007

2001 2Nd Ave Ste 201, Summerville, SC 29486

Open in the dashboard

General payments

$12,354

478 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thyra Maltese of Summerville, SC is reported in the CMS Open Payments database as having received $12,354 across 478 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,322 60
2024 General $5,560 123
2023 General $2,355 121
2022 General $1,900 97
2021 General $1,216 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thyra Maltese
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Thyra Maltese were reported at $1,322. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Thyra Maltese Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $1,216 $132 $37–$438 $132
2022 $1,900 $155 $48–$522 $149
2023 $2,355 $167 $52–$557 $160
2024 $5,560 $178 $55–$600 $164
2025 $1,322 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Sobi, Inc $2,987 8 payments
  2. AbbVie, Inc. $2,066 101 payments
  3. Janssen Biotech, Inc. $1,863 99 payments
  4. Amgen Inc. $1,066 49 payments
  5. Lilly USA, LLC $810 39 payments
  6. AstraZeneca Pharmaceuticals LP $697 33 payments
  7. UCB, Inc. $682 37 payments
  8. Novartis Pharmaceuticals Corporation $494 26 payments
  9. GlaxoSmithKline, LLC. $392 21 payments
  10. Organon LLC $240 9 payments
  11. Other $1,058 56 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,564 474 payments
  2. Consulting Fee $2,318 1 payment
  3. Travel and Lodging $408 1 payment
  4. Education $63 2 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,654 89 payments
  2. RINVOQ $1,576 81 payments
  3. TALTZ $810 39 payments
  4. SIMPONI ARIA $783 46 payments
  5. SAPHNELO $603 29 payments
  6. SKYRIZI $531 23 payments
  7. SYNAGIS $516 2 payments
  8. Enbrel $439 20 payments
  9. Cimzia $416 23 payments
  10. BENLYSTA $392 21 payments
  11. Other $4,485 212 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,312

Median for Physician Assistant: 241

Drug cost

$537,934

Median for Physician Assistant: $4,110

Branded share of claims

25.6%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Enbrel Sureclick Etanercept Brand 17 $154,117
Orencia Clickject Abatacept Brand 22 $133,116
Cimzia (2 Pack) Certolizumab Pegol Brand 19 $120,122
Benlysta Belimumab Brand 11 $49,142
Otezla Apremilast Brand 12 $46,674
Hydroxychloroquine Sulfate Generic 217 $10,366
Leflunomide Generic 96 $5,926
Methotrexate Methotrexate Sodium Brand 240 $4,279
Pregabalin Generic 48 $2,455
Mycophenolate Mofetil Generic 26 $2,410

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$71,376

Of which drugs: $1,294

Medicare patients

423

Average age 72

Services billed

3,951

335 women, 88 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Osteoporosis 37%
Diabetes 31%
Chronic kidney disease 29%
Depression 25%
Ischemic heart disease 21%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 1 mg J1010 Office 19 790 $81
Injection, methylprednisolone acetate, 40 mg J1030 Office 14 17 $76

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SYNAGIS
$516 — —
RINVOQ
$342 — —
TREMFYA
$295 — —
SKYRIZI
$284 — —
COSENTYX
$270 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

478 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record